
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4010646/publications.pdf Version: 2024-02-01



Διές Ιινιμαστ

#	Article	IF	CITATIONS
1	2018 ESC/ESH Guidelines for the management of arterial hypertension. European Heart Journal, 2018, 39, 3021-3104.	1.0	6,826
2	2013 ESH/ESC Guidelines for the management of arterial hypertension. European Heart Journal, 2013, 34, 2159-2219.	1.0	5,681
3	2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal, 2021, 42, 3599-3726.	1.0	5,558
4	2014 ESC/EACTS Guidelines on myocardial revascularization. European Heart Journal, 2014, 35, 2541-2619.	1.0	4,141
5	2013 ESC guidelines on the management of stable coronary artery disease. European Heart Journal, 2013, 34, 2949-3003.	1.0	3,915
6	2014 ESC Guidelines on the diagnosis and treatment of aortic diseases. European Heart Journal, 2014, 35, 2873-2926.	1.0	3,549
7	2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy. European Heart Journal, 2014, 35, 2733-2779.	1.0	3,469
8	2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. European Heart Journal, 2020, 41, 255-323.	1.0	2,811
9	2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism. European Heart Journal, 2014, 35, 3033-3080.	1.0	2,591
10	2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. European Heart Journal, 2021, 42, 3227-3337.	1.0	2,517
11	Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. European Heart Journal, 2013, 34, 2636-2648.	1.0	2,436
12	2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy. European Heart Journal, 2013, 34, 2281-2329.	1.0	2,176
13	2014 ESC/EACTS Guidelines on myocardial revascularization. European Journal of Cardio-thoracic Surgery, 2014, 46, 517-592.	0.6	2,164
14	2015 ESC Guidelines for the diagnosis and management of pericardial diseases. European Heart Journal, 2015, 36, 2921-2964.	1.0	1,768
15	ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. European Heart Journal, 2013, 34, 3035-3087.	1.0	1,758
16	2014 ESC/ESA Guidelines on non-cardiac surgery: cardiovascular assessment and management. European Heart Journal, 2014, 35, 2383-2431.	1.0	1,253
17	2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Journal of Heart Failure, 2022, 24, 4-131.	2.9	820
18	Proposal for a revised definition of dilated cardiomyopathy, hypokinetic non-dilated cardiomyopathy, and its implications for clinical practice: a position statement of the ESC working group on myocardial and pericardial diseases. European Heart Journal, 2016, 37, 1850-1858.	1.0	757

#	Article	IF	CITATIONS
19	Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey. European Journal of Clinical Investigation, 2004, 34, 236-242.	1.7	701
20	Darapladib for Preventing Ischemic Events in Stable Coronary Heart Disease. New England Journal of Medicine, 2014, 370, 1702-1711.	13.9	467
21	Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases. European Heart Journal, 2021, 42, 1554-1568.	1.0	434
22	Fabry disease revisited: Management and treatment recommendations for adult patients. Molecular Genetics and Metabolism, 2018, 123, 416-427.	0.5	391
23	Diagnostic work-up in cardiomyopathies: bridging the gap between clinical phenotypes and final diagnosis. A position statement from the ESC Working Group on Myocardial and Pericardial Diseases. European Heart Journal, 2013, 34, 1448-1458.	1.0	346
24	Cardiac manifestations of Anderson-Fabry disease: results from the international Fabry outcome survey. European Heart Journal, 2007, 28, 1228-1235.	1.0	320
25	Natural course of Fabry disease: changing pattern of causes of death in FOS - Fabry Outcome Survey. Journal of Medical Genetics, 2009, 46, 548-552.	1.5	259
26	Enzyme replacement therapy with agalsidase alfa in patients with Fabry's disease: an analysis of registry data. Lancet, The, 2009, 374, 1986-1996.	6.3	246
27	Effect of Intra-arrest Transport, Extracorporeal Cardiopulmonary Resuscitation, and Immediate Invasive Assessment and Treatment on Functional Neurologic Outcome in Refractory Out-of-Hospital Cardiac Arrest. JAMA - Journal of the American Medical Association, 2022, 327, 737.	3.8	242
28	New insights in cardiac structural changes in patients with Fabry's disease. American Heart Journal, 2000, 139, 1101-1108.	1.2	226
29	Heart failure in cardiomyopathies: a position paper from the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2019, 21, 553-576.	2.9	224
30	2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. European Journal of Preventive Cardiology, 2022, 29, 5-115.	0.8	220
31	The heart in Anderson-Fabry disease and other lysosomal storage disorders. Heart, 2007, 93, 528-535.	1.2	211
32	Serial left ventricular adaptations in world-class professional cyclists. Journal of the American College of Cardiology, 2004, 44, 144-149.	1.2	209
33	Fabry disease: overall effects of agalsidase alfa treatment. European Journal of Clinical Investigation, 2004, 34, 838-844.	1.7	197
34	Ethnic-Specific Normative Reference Values for Echocardiographic LAÂand LV Size, LV Mass, and Systolic Function. JACC: Cardiovascular Imaging, 2015, 8, 656-665.	2.3	182
35	Diagnosis and management of myocardial involvement in systemic immune-mediated diseases: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Disease. European Heart Journal, 2017, 38, 2649-2662.	1.0	163
36	Triage strategy for urgent management of cardiac tamponade: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. European Heart Journal, 2014, 35, 2279-2284.	1.0	154

#	Article	IF	CITATIONS
37	Diagnosis and treatment of cardiac amyloidosis. A position statement of the European Society of Cardiology <scp>W</scp> orking <scp>G</scp> roup on <scp>M</scp> yocardial and <scp>P</scp> ericardial <scp>D</scp> iseases. European Journal of Heart Failure, 2021, 23, 512-526.	2.9	153
38	Onset and progression of the Anderson–Fabry disease related cardiomyopathy. International Journal of Cardiology, 2008, 130, 367-373.	0.8	141
39	Induction of mild hypothermia in cardiac arrest survivors presenting with cardiogenic shock syndrome. Acta Anaesthesiologica Scandinavica, 2008, 52, 188-194.	0.7	133
40	Cardiovascular Events in Patients With Fabry Disease. Journal of the American College of Cardiology, 2011, 57, 1093-1099.	1.2	132
41	Cause of Death and Predictors of All ause Mortality in Anticoagulated Patients With Nonvalvular Atrial Fibrillation: Data From ROCKET AF. Journal of the American Heart Association, 2016, 5, e002197.	1.6	127
42	Cardiac manifestations in Fabry disease. Journal of Inherited Metabolic Disease, 2001, 24, 75-83.	1.7	124
43	Baseline characteristics and hospital mortality in the Acute Heart Failure Database (AHEAD) Main registry. Critical Care, 2011, 15, R291.	2.5	124
44	European expert consensus statement on therapeutic goals in Fabry disease. Molecular Genetics and Metabolism, 2018, 124, 189-203.	0.5	122
45	The effect of enzyme replacement therapy on clinical outcomes in male patients with Fabry disease: A systematic literature review by a European panel of experts. Molecular Genetics and Metabolism Reports, 2019, 19, 100454.	0.4	120
46	Cardiac Involvement in Fabry Disease. Journal of the American College of Cardiology, 2021, 77, 922-936.	1.2	109
47	Heart Failure Association of the ESC, Heart Failure Society of America and Japanese Heart Failure Society Position statement on endomyocardial biopsy. European Journal of Heart Failure, 2021, 23, 854-871.	2.9	105
48	Cardiac and Vascular Hypertrophy in Fabry Disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 2006, 26, 839-844.	1.1	101
49	Time to treatment benefit for adult patients with Fabry disease receiving agalsidase β: data from the Fabry Registry. Journal of Medical Genetics, 2016, 53, 495-502.	1.5	101
50	Hyperinvasive approach to out-of hospital cardiac arrest using mechanical chest compression device, prehospital intraarrest cooling, extracorporeal life support and early invasive assessment compared to standard of care. A randomized parallel groups comparative study proposal. "Prague OHCA study― Journal of Translational Medicine, 2012, 10, 163.	1.8	99
51	An expert consensus document on the management of cardiovascular manifestations of Fabry disease. European Journal of Heart Failure, 2020, 22, 1076-1096.	2.9	96
52	Intracoronary Injection of Autologous Bone Marrow-Derived Mononuclear Cells in Patients With Large Anterior Acute Myocardial Infarction. Journal of the American College of Cardiology, 2007, 49, 2373-2374.	1.2	87
53	Left ventricular hypertrophy in Fabry disease: a practical approach to diagnosis. European Heart Journal, 2013, 34, 802-808.	1.0	83
54	Coronary versus carotid blood flow and coronary perfusion pressure in a pig model of prolonged cardiac arrest treated by different modes of venoarterial ECMO and intraaortic balloon counterpulsation. Critical Care, 2012, 16, R50.	2.5	77

#	Article	IF	CITATIONS
55	The current role of next-generation DNA sequencing in routine care of patients with hereditary cardiovascular conditions: a viewpoint paper of the European Society of Cardiology working group on myocardial and pericardial diseases and members of the European Society of Human Genetics. European Heart Journal, 2015, 36, 1367-1370.	1.0	75
56	Analysis of left ventricular mass in untreated men and in men treated with agalsidase-β: data from the Fabry Registry. Genetics in Medicine, 2013, 15, 958-965.	1.1	74
57	Wall thickening of carotid and femoral arteries in male subjects with isolated hypercholesterolemia. Atherosclerosis, 1995, 113, 141-151.	0.4	72
58	Current Diagnostic and Therapeutic Aspects of Eosinophilic Myocarditis. BioMed Research International, 2016, 2016, 1-6.	0.9	72
59	Phenotypic characteristics of the p.Asn215Ser (p.N215S) <i>G<scp>LA</scp></i> mutation in male and female patients with Fabry disease: A multicenter Fabry Registry study. Molecular Genetics & amp; Genomic Medicine, 2018, 6, 492-503.	0.6	70
60	Pilot study of combined blockade of the renin–angiotensin system in essential hypertensive patients. Journal of Hypertension, 2000, 18, 1139-1147.	0.3	67
61	Virtual Histology Evaluation of Atherosclerosis Regression During Atorvastatin and Ezetimibe Administration - HEAVEN Study Circulation Journal, 2012, 76, 176-183.	0.7	67
62	Cardiac involvement in Wilson disease. Journal of Inherited Metabolic Disease, 2002, 25, 269-277.	1.7	64
63	Prevalence of Uncontrolled Hypertension in Patients With Fabry Disease. American Journal of Hypertension, 2006, 19, 782-787.	1.0	64
64	The Role of Cardiac Imaging in the Diagnosis and Management of Anderson-Fabry Disease. JACC: Cardiovascular Imaging, 2019, 12, 1230-1242.	2.3	64
65	Long-term survival following acute heart failure: The Acute Heart Failure Database Main registry (AHEAD Main). European Journal of Internal Medicine, 2013, 24, 151-160.	1.0	59
66	AHEAD score — Long-term risk classification in acute heart failure. International Journal of Cardiology, 2016, 202, 21-26.	0.8	59
67	Aortic remodelling in Fabry disease. European Heart Journal, 2010, 31, 347-353.	1.0	58
68	Carotid artery and left ventricular structural relationship in asymptomatic men at risk for cardiovascular disease. Atherosclerosis, 1996, 127, 103-112.	0.4	56
69	A validated disease severity scoring system for Fabry disease. Molecular Genetics and Metabolism, 2010, 99, 283-290.	0.5	56
70	Epidemiology and long-term survival of pulmonary arterial hypertension in the Czech Republic: a retrospective analysis of a nationwide registry. BMC Pulmonary Medicine, 2014, 14, 45.	0.8	56
71	European Cardiomyopathy Pilot Registry: EURObservational Research Programme of the European Society of Cardiology. European Heart Journal, 2016, 37, 164-173.	1.0	56
72	Extra corporeal membrane oxygenation in the therapy of cardiogenic shock (<scp>ECMO S</scp>): rationale and design of the multicenter randomized trial. European Journal of Heart Failure, 2017, 19, 124-127.	2.9	55

#	Article	IF	CITATIONS
73	Natural history of the respiratory involvement in Anderson–Fabry disease. Journal of Inherited Metabolic Disease, 2007, 30, 790-799.	1.7	53
74	A rationale for early extracorporeal membrane oxygenation in patients with postinfarction ventricular septal rupture complicated by cardiogenic shock. European Journal of Heart Failure, 2017, 19, 97-103.	2.9	52
75	Prevalence of Fabry disease in male patients with unexplained left ventricular hypertrophy in primary cardiology practice: prospective Fabry cardiomyopathy screening study (FACSS). Journal of Inherited Metabolic Disease, 2014, 37, 455-460.	1.7	47
76	Cardiac challenges in patients with Fabry disease. International Journal of Cardiology, 2010, 141, 3-10.	0.8	46
77	Preclinical changes of extracoronary arterial structures as indicators of coronary atherosclerosis in men. Journal of Hypertension, 1998, 16, 157-163.	0.3	45
78	Right Ventricular Involvement in Fabry Disease. Journal of the American Society of Echocardiography, 2008, 21, 1265-1268.	1.2	45
79	Lipoproteinâ€Associated Phospholipase A ₂ Activity Is a Marker of Risk But Not a Useful Target for Treatment in Patients With Stable Coronary Heart Disease. Journal of the American Heart Association, 2016, 5, .	1.6	44
80	Interleukin 6 and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Chronic Coronary Syndrome. JAMA Cardiology, 2021, 6, 1440.	3.0	43
81	Veno-arterial ECMO in severe acute right ventricular failure with pulmonary obstructive hemodynamic pattern. Journal of Invasive Cardiology, 2010, 22, 365-9.	0.4	43
82	Presence of Borrelia burgdorferi in endomyocardial biopsies in patients with new-onset unexplained dilated cardiomyopathy. Medical Microbiology and Immunology, 2010, 199, 139-143.	2.6	40
83	Increased carotid intima–media thickness in the absence of atherosclerotic plaques in an adult population with Fabry disease. Acta Paediatrica, International Journal of Paediatrics, 2006, 95, 63-68.	0.7	40
84	Effect of agalsidase alfa replacement therapy on fabry disease—related hypertrophic cardiomyopathy: A 12- to 36-month, retrospective, blinded echocardiographic pooled analysis. Clinical Therapeutics, 2009, 31, 1966-1976.	1.1	39
85	Percutaneous Mechanical Thrombectomy Using Rotarex® S Device in Acute Limb Ischemia in Infrainguinal Occlusions. BioMed Research International, 2017, 2017, 1-8.	0.9	36
86	Hyperhidrosis: a new and often early symptom in Fabry disease. International experience and data from the Fabry Outcome Survey. International Journal of Clinical Practice, 2006, 60, 1053-1059.	0.8	34
87	Uric acid, allopurinol therapy, and mortality in patients with acute heart failure—results of the Acute HEart FAilure Database registry. Journal of Critical Care, 2012, 27, 737.e11-737.e24.	1.0	34
88	30-year trends in major cardiovascular risk factors in the Czech population, Czech MONICA and Czech post-MONICA, 1985 – 2016/17. PLoS ONE, 2020, 15, e0232845.	1.1	34
89	Vascular and cardiac remodeling in world class professional cyclists. American Heart Journal, 1998, 136, 818-823.	1.2	33
90	Severe Allergic Dermatitis After Closure of Foramen Ovale With Amplatzer Occluder. Annals of Thoracic Surgery, 2013, 96, e57-e59.	0.7	31

#	Article	IF	CITATIONS
91	Heart Failure Association, Heart Failure Society of America, and Japanese Heart Failure Society Position Statement on Endomyocardial Biopsy. Journal of Cardiac Failure, 2021, 27, 727-743.	0.7	29
92	Echographic assessment of carotid and femoral arterial structure in men with essential hypertension. American Journal of Hypertension, 1996, 9, 126-136.	1.0	27
93	Effect of Preload Reduction by Hemodialysis on Conventional and Novel Echocardiographic Parameters of Left Ventricular Structure and Function. Echocardiography, 2008, 25, 162-168.	0.3	27
94	Advances in accelerometry for cardiovascular patients: a systematic review with practical recommendations. ESC Heart Failure, 2020, 7, 2021-2031.	1.4	26
95	Anemia is a new complication in Fabry disease: Data from the Fabry Outcome Survey. Kidney International, 2005, 67, 1955-1960.	2.6	24
96	Serum cardiac markers response to biphasic and monophasic electrical cardioversion for supraventricular tachyarrhythmia—a randomised study. Resuscitation, 2006, 70, 423-431.	1.3	24
97	Early Cardiac Changes in Children with Anderson–Fabry Disease. JIMD Reports, 2013, 11, 53-64.	0.7	23
98	Study of urinary proteomes in Anderson-Fabry disease. Renal Failure, 2010, 32, 1202-1209.	0.8	22
99	Fabry Disease: Percutaneous Transluminal Septal Myocardial Ablation Markedly Improved Symptomatic Left Ventricular Hypertrophy and Outflow Tract Obstruction in a Classically Affected Male. Echocardiography, 2005, 22, 333-339.	0.3	21
100	Early indicators of disease progression in Fabry disease that may indicate the need for disease-specific treatment initiation: findings from the opinion-based PREDICT-FD modified Delphi consensus initiative. BMJ Open, 2020, 10, e035182.	0.8	20
101	Prevalence and clinical significance of liver function abnormalities in patients with acute heart failure. Biomedical Papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia, 2015, 159, 429-436.	0.2	20
102	Effect of a 6-month pedometer-based walking intervention on functional capacity in patients with chronic heart failure with reduced (HFrEF) and with preserved (HFpEF) ejection fraction: study protocol for two multicenter randomized controlled trials. Journal of Translational Medicine, 2017, 15, 153.	1.8	19
103	Common presentation of rare diseases: Left ventricular hypertrophy and diastolic dysfunction. International Journal of Cardiology, 2018, 257, 344-350.	0.8	19
104	Positive Influence of Being Overweight/Obese on Long Term Survival in Patients Hospitalised Due to Acute Heart Failure. PLoS ONE, 2015, 10, e0117142.	1.1	18
105	Plaque volume and plaque risk profile in diabetic vs. non-diabetic patients undergoing lipid-lowering therapy: a study based on 3D intravascular ultrasound and virtual histology. Cardiovascular Diabetology, 2017, 16, 156.	2.7	18
106	Intravascular ultrasound assessment of coronary artery involvement in Fabry disease. Journal of Inherited Metabolic Disease, 2008, 31, 753-760.	1.7	17
107	Inflammatory response in patients undergoing hip surgery due to osteoarthrosis or different types of hip fractures. Osteoarthritis and Cartilage, 2008, 16, 26-33.	0.6	17
108	Long-term prognostic impact of hyponatremia in the ST-elevation myocardial infarction. Scandinavian Journal of Clinical and Laboratory Investigation, 2011, 71, 38-44.	0.6	17

#	Article	IF	CITATIONS
109	Early and subacute inflammatory response and long-term survival after hip trauma and surgery. Archives of Gerontology and Geriatrics, 2015, 60, 431-436.	1.4	17
110	The prevalence and clinical outcome of supraventricular tachycardia in different etiologies of pulmonary hypertension. PLoS ONE, 2021, 16, e0245752.	1.1	17
111	Lack of Association of Angiotensin-converting Enzyme and Angiotensinogen Genes Polymorphisms with Left Ventricular Structure in Young Normotensive Men. Blood Pressure, 2000, 9, 47-51.	0.7	16
112	Older age and type of surgery predict the early inflammatory response to hip trauma mediated by interleukin-6 (IL-6). Archives of Gerontology and Geriatrics, 2010, 51, e1-e6.	1.4	16
113	Hypertrophic Cardiomyopathy Due to the Mitochondrial DNA Mutation m.3303C>T Diagnosed in an Adult Male. International Heart Journal, 2012, 53, 383-387.	0.5	16
114	Multimodality imaging in Fabry cardiomyopathy: from early diagnosis to therapeutic targets. European Heart Journal Cardiovascular Imaging, 2018, 19, 1313-1322.	0.5	16
115	Comparison of early diastolic mitral annular velocity and flow propagation velocity in detection of mild to moderate left ventricular diastolic dysfunction. European Journal of Echocardiography, 2004, 5, 196-204.	2.3	15
116	Early diastolic mitral annular velocity and color M-mode flow propagation velocity in the evaluation of left ventricular diastolic function in patients with Fabry disease. Heart and Vessels, 2006, 21, 13-19.	0.5	15
117	Evaluation of the efficacy and safety of three dosing regimens of agalsidase alfa enzyme replacement therapy in adults with Fabry disease. Drug Design, Development and Therapy, 2015, 9, 3435.	2.0	15
118	Recent-onset dilated cardiomyopathy associated with Borrelia burgdorferi infection. Herz, 2015, 40, 892-897.	0.4	15
119	Gene variants at FTO, 9p21, and 2q36.3 are age-independently associated with myocardial infarction in Czech men. Clinica Chimica Acta, 2016, 454, 119-123.	0.5	15
120	Comparison of three office blood pressure measurement techniques and their effect on hypertension prevalence in the general population. Journal of Hypertension, 2020, 38, 656-662.	0.3	15
121	Association between cardiac energy metabolism and gain of left ventricular mass in Fabry disease. International Journal of Cardiology, 2010, 144, 337-339.	0.8	14
122	Pulmonary arterial hypertension associated with systemic sclerosis in the Czech Republic. Clinical Rheumatology, 2012, 31, 557-561.	1.0	14
123	Placental growth factor may predict increased left ventricular mass index in patients with mild to moderate chronic kidney disease – a prospective observational study. BMC Nephrology, 2013, 14, 142.	0.8	14
124	Association of â~344/T/C aldosterone synthase polymorphism (CYP11B2) with left ventricular structure and humoral parameters in young normotensive men. Blood Pressure, 2004, 13, 158-163.	0.7	13
125	Hemodynamic Instability after Pulmonary Endarterectomy for Chronic Thromboembolic Pulmonary Hypertension Correlates with Cytokine Network Hyperstimulation. European Surgical Research, 2009, 43, 39-46.	0.6	13
126	Cardiac Safety in Vascular Access Surgery and Maintenance. Contributions To Nephrology, 2015, 184, 75-86.	1.1	13

#	Article	IF	CITATIONS
127	Brain perfusion evaluated by regional tissue oxygenation as a possible quality indicator of ongoing cardiopulmonary resuscitation. An experimental porcine cardiac arrest study. Perfusion (United) Tj ETQq1 1 0.7	7843 0.\$ rgB ⁻	T /@serlock 1
128	Cardiomyopathy and kidney function in agalsidase betaâ€ŧreated female Fabry patients: a preâ€ŧreatment vs. postâ€ŧreatment analysis. ESC Heart Failure, 2020, 7, 825-834.	1.4	13
129	ECG in patients with acute heart failure can predict in-hospital and long-term mortality. Internal and Emergency Medicine, 2014, 9, 283-291.	1.0	12
130	Hyperuricemia treatment in acute heart failure patients does not improve their longâ€ŧerm prognosis: A propensity score matched analysis from the AHEAD registry. Clinical Cardiology, 2019, 42, 720-727.	0.7	12
131	Balloon Pulmonary Angioplasty in Patients with Chronic Thromboembolic Pulmonary Hypertension: Impact on Clinical and Hemodynamic Parameters, Quality of Life and Risk Profile. Journal of Clinical Medicine, 2020, 9, 3608.	1.0	12
132	Standard ECG for differential diagnosis between Anderson-Fabry disease and hypertrophic cardiomyopathy. Heart, 2022, 108, 54-60.	1.2	12
133	Treatment of Takotsubo Cardiomyopathy. Current Pharmaceutical Design, 2010, 16, 2905-2909.	0.9	11
134	Intracoronary injection of autologous bone marrow-derived mononuclear cells in patients with large anterior acute myocardial infarction and left ventricular dysfunction: A 24- month follow up study. Bratislava Medical Journal, 2012, 113, 220-227.	0.4	11
135	The left atrial substrate plays a significant role in the development of complex atrial tachycardia in patients with precapillary pulmonary hypertension. BMC Cardiovascular Disorders, 2019, 19, 157.	0.7	11
136	Association between common cardiovascular risk factors and clinical phenotype in patients with hypertrophic cardiomyopathy from the European Society of Cardiology (ESC) EurObservational Research Programme (EORP) Cardiomyopathy/Myocarditis registry. European Heart Journal Quality of Care & Clinical Outcomes, 2022, 9, 42-53.	1.8	11
137	Nationwide screening for Fabry disease in unselected stroke patients. PLoS ONE, 2021, 16, e0260601.	1.1	11
138	Treatment of Anderson Fabry disease. Heart, 2008, 94, 138-139.	1.2	10
139	Risk of in-hospital mortality identified according to the typology of patients with acute heart failure: Classification tree analysis on data from the Acute Heart Failure Database–Main registry. Journal of Critical Care, 2013, 28, 250-258.	1.0	10
140	Microcirculatory blood flow during cardiac arrest and cardiopulmonary resuscitation does not correlate with global hemodynamics: an experimental study. Journal of Translational Medicine, 2016, 14, 163.	1.8	10
141	Effects of Baseline Left Ventricular Hypertrophy and Decreased Renal Function on Cardiovascular and Renal Outcomes in Patients with Fabry Disease Treated with Agalsidase Alfa: A Fabry Outcome Survey Study. Clinical Therapeutics, 2020, 42, 2321-2330.e0.	1.1	10
142	Gender differences in total cholesterol levels in patients with acute heart failure and its importance for short and long time prognosis. Biomedical Papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia, 2012, 156, 21-22.	0.2	10
143	Association between tyrosine hydroxylase polymorphisms and left ventricular structure in young normotensive men. British Journal of Biomedical Science, 2002, 59, 90-94.	1.2	9
144	Renal denervation decreases effective refractory period but not inducibility of ventricular fibrillation in a healthy porcine biomodel: a case control study. Journal of Translational Medicine, 2015, 13, 4.	1.8	9

#	Article	IF	CITATIONS
145	Atrial fibrillation and atrial tachycardia in patients with chronic thromboembolic pulmonary hypertension treated with pulmonary endarterectomy. European Heart Journal Supplements, 2020, 22, F30-F37.	0.0	9
146	Trends in the treatment and survival of heart failure patients: a nationwide populationâ€based study in the Czech Republic. ESC Heart Failure, 2021, 8, 3800-3808.	1.4	9
147	Fabry disease - Vascular manifestations. Vasa - European Journal of Vascular Medicine, 2010, 39, 123-131.	0.6	9
148	Comparison of early diastolic annular velocities measured at various sites of mitral annulus in detection of mild to moderate left ventricular diastolic dysfunction. Heart and Vessels, 2007, 22, 67-72.	0.5	8
149	Erectile Dysfunction in Young Myocardial Infarction Survivors: Evaluation, Follow Up. American Journal of Men's Health, 2017, 11, 1739-1744.	0.7	8
150	Prompt Agalsidase Alfa Therapy Initiation is Associated with Improved Renal and Cardiovascular Outcomes in a Fabry Outcome Survey Analysis. Drug Design, Development and Therapy, 2021, Volume 15, 3561-3572.	2.0	8
151	Papillary Fibroelastoma Arising from the Left Ventricular Apex Associated with Nonspecific Systemic Symptoms. Echocardiography, 2008, 25, 526-528.	0.3	7
152	Herpes simplex virus-induced cardiomyopathy successfully treated with acyclovir. Wiener Klinische Wochenschrift, 2010, 122, 592-595.	1.0	7
153	Does previous hypertension affect outcome in acute heart failure?. European Journal of Internal Medicine, 2011, 22, 591-596.	1.0	7
154	Endovascular treatment combined with stratified surgery is effective in the management of venous thoracic outlet syndrome complications: a long term ultrasound follow-up study in patients with thrombotic events due to venous thoracic outlet syndrome. Heart and Vessels, 2011, 26, 616-621.	0.5	7
155	Needle fragment embolism into the right ventricle: a rare cause of chest pain case report and literature review. Wiener Klinische Wochenschrift, 2016, 128, 215-220.	1.0	7
156	Effect of Pulsatility on Microcirculation in Patients Treated with Extracorporeal Cardiopulmonary Resuscitation: A Pilot Study. ASAIO Journal, 2017, 63, 386-391.	0.9	7
157	Late diagnosis of mucopolysaccharidosis type IVB and successful aortic valve replacement in a 60-year-old female patient. Cardiovascular Pathology, 2018, 35, 52-56.	0.7	7
158	The development of persistent thrombotic masses in patients with deep venous thrombosis randomized to long-term anticoagulation treatment. Vasa - European Journal of Vascular Medicine, 2009, 38, 238-244.	0.6	7
159	Utility of Electrocardiogram for Predicting Increased Left Ventricular Mass in Asymptomatic Men at Risk for Cardiovascular Disease. American Journal of Hypertension, 1998, 11, 861-865.	1.0	6
160	Increased carotid intima–media thickness in the absence of atherosclerotic plaques in an adult population with Fabry disease. Acta Paediatrica, International Journal of Paediatrics, 2006, 95, 63-68.	0.7	6
161	Cardiac Structural and Functional Changes in Competitive Amateur Cyclists. Echocardiography, 2010, 27, 11-16.	0.3	6
162	Are pulmonary artery pulsatility indexes able to differentiate chronic pulmonary thromboembolism from pulmonary arterial hypertension? An echocardiographic and catheterization study. Heart and Vessels, 2011, 26, 176-182.	0.5	6

#	Article	IF	CITATIONS
163	Feasibility of cerebral blood flow and oxygenation monitoring by continuous transcranial Doppler combined with cerebral oximetry in a patient with refractory cardiac arrest treated by extracorporeal life support. Perfusion (United Kingdom), 2014, 29, 534-538.	0.5	6
164	Arrhythmogenic substrate at the interventricular septum as a target site for radiofrequency catheter ablation of recurrent ventricular tachycardia in left dominant arrhythmogenic cardiomyopathy. BMC Cardiovascular Disorders, 2015, 15, 18.	0.7	6
165	Echocardiography in coronary artery disease. Cor Et Vasa, 2015, 57, e408-e418.	0.1	6
166	Echocardiography and cardiac resynchronization therapy. Cor Et Vasa, 2016, 58, e340-e351.	0.1	6
167	A congenital diverticulum of the left ventricular apex manifested by stroke and recurrent ventricular tachycardia. Cardiovascular Pathology, 2017, 28, 3-6.	0.7	6
168	The effect of renal denervation in an experimental model of chronic renal insufficiency, The REmnant kidney Denervation In Pigs study (REDIP study). Journal of Translational Medicine, 2017, 15, 215.	1.8	6
169	Acute heart failure databases in specialist departments of cardiology. Cor Et Vasa, 2008, 50, 12-21.	0.1	6
170	Safety and benefit of incretin-based therapies in patients with type 2 diabetes: learnings and reflections. Expert Opinion on Drug Safety, 2022, 21, 291-293.	1.0	6
171	Therapeutic hypothermia in cardiac arrest survivors: A survey of practice in the Czech Republic. Resuscitation, 2008, 77, 419-420.	1.3	5
172	Coronary CT angiography. Cor Et Vasa, 2015, 57, e425-e432.	0.1	5
173	Worse prognosis of realâ€world patients with acute heart failure from the Czech AHEAD registry in comparison to patients from the RELAXâ€AHF trial. ESC Heart Failure, 2017, 4, 8-15.	1.4	5
174	In patients with stable coronary heart disease, low-density lipoprotein-cholesterol levels < 70 mg/dL and glycosylated hemoglobin A1c < 7% are associated with lower major cardiovascular events. American Heart Journal, 2020, 225, 97-107.	1.2	5
175	Combined valve replacement and aortocoronary bypass in an adult mucopolysaccharidosis type VII patient. Cardiovascular Pathology, 2021, 50, 107297.	0.7	5
176	Narrative review on Morbus Fabry: diagnosis and management of cardiac manifestations. Cardiovascular Diagnosis and Therapy, 2021, 11, 650-660.	0.7	5
177	Coronary angiography and percutaneous coronary intervention in cardiac arrest patients without return of spontaneous circulation. Resuscitation, 2022, 175, 133-141.	1.3	5
178	Pitfalls of Xâ€chromosome inactivation testing in females with Fabry disease. American Journal of Medical Genetics, Part A, 2022, 188, 1979-1989.	0.7	5
179	Atteinte respiratoire de la maladie de Fabry. Medecine/Sciences, 2005, 21, 37-39.	0.0	4
180	Five year two center retrospective analysis of patients with toxic digoxin serum concentration. International Journal of Cardiology, 2011, 146, 447-448.	0.8	4

#	Article	IF	CITATIONS
181	Early vancomycin, amikacin and gentamicin concentrations in pulmonary artery and pulmonary tissue are not affected by VA ECMO (venoarterial extracorporeal membrane oxygenation) in a pig model of prolonged cardiac arrest. Pulmonary Pharmacology and Therapeutics, 2013, 26, 655-660.	1.1	4
182	Median Frequencies of Prolonged Ventricular Fibrillation treated by V-A ECMO Correspond to a Return of Spontaneous Circulation Rate. International Journal of Artificial Organs, 2014, 37, 48-57.	0.7	4
183	Electromuscular Incapacitating Devices Discharge and Risk of Severe Bradycardia. American Journal of Forensic Medicine and Pathology, 2015, 36, 94-98.	0.4	4
184	Multivariate Analysis of Correspondence between Left Atrial Volumes Assessed by Echocardiography and 3-Dimensional Electroanatomic Mapping in Patients with Atrial Fibrillation. PLoS ONE, 2016, 11, e0152553.	1.1	4
185	Uric Acid as a Marker of Mortality and Morbidity in Fabry Disease. PLoS ONE, 2016, 11, e0166290.	1.1	4
186	The diagnostic performance of cardiac magnetic resonance in detection of myocardial involvement in <scp>AL</scp> amyloidosis. Clinical Physiology and Functional Imaging, 2016, 36, 218-224.	0.5	4
187	A rare cause of acute limb ischemia of both upper and lower limbs caused by prolonged vasospasm. Cor Et Vasa, 2017, 59, e503-e506.	0.1	4
188	Multiple thrombophilia mutations as aÂpossible cause of premature myocardial infarction. Wiener Klinische Wochenschrift, 2017, 129, 503-508.	1.0	4
189	Comparison of echocardiographic parameters in Fabry cardiomyopathy and lightâ€chain cardiac amyloidosis. Echocardiography, 2018, 35, 1755-1763.	0.3	4
190	Which serum uric acid levels are associated with increased cardiovascular risk in the general adult population?. Journal of Clinical Hypertension, 2020, 22, 897-905.	1.0	4
191	Primary aldosteronism in a general population sample. The Czech post-MONICA study. Blood Pressure, 2020, 29, 191-198.	0.7	4
192	The impact of riociguat on clinical parameters and quality of life in patients with chronic thromboembolic pulmonary hypertension - results of a retrospective clinical registry. Biomedical Papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia, 2021, 165, 157-161.	0.2	4
193	New Therapeutic Aspects of Inflammatory Cardiomyopathy. Current Pharmaceutical Design, 2014, 21, 459-465.	0.9	4
194	Heart Rate Turbulence after Ventricular Pacing Trains During Programmed Ventricular Stimulation. PACE - Pacing and Clinical Electrophysiology, 2007, 30, S170-3.	0.5	3
195	Preload Dependence of the Time Interval between Onsets of Mitral Inflow and Early Diastolic Mitral Annular Velocity: A Study in Healthy Subjects. Echocardiography, 2008, 25, 249-255.	0.3	3
196	Puncture and wiring of extracorporeal circuit for cannula safe removal or exchange. Perfusion (United Kingdom), 2016, 31, 604-607.	0.5	3
197	e-Health: A position statement of the European Society of Cardiology. Summary of the document prepared by the Czech Society of Cardiology. Cor Et Vasa, 2017, 59, e204-e207.	0.1	3
198	The phenotypic characteristics of the p.N215S Fabry disease genotype in male and female patients: a multi-center Fabry Registry study. Molecular Genetics and Metabolism, 2017, 120, S51-S52.	0.5	3

#	Article	IF	CITATIONS
199	Heart Failure Caused by Misdiagnosed Subaortic Stenosis in Adulthood: Lesson for Daily Practice. Annals of Thoracic Surgery, 2017, 104, e91.	0.7	3
200	Serum Bilirubin Levels and Promoter Variations in <i>HMOX1</i> and <i>UGT1A1</i> Genes in Patients with Fabry Disease. Oxidative Medicine and Cellular Longevity, 2017, 2017, 1-6.	1.9	3
201	Takotsubo cardiomyopathy in a patient with essential thrombocythemia treated with anagrelide: Case report. Cor Et Vasa, 2018, 60, e327-e330.	0.1	3
202	Simplified apical four hamber view evaluation of relative apical sparing of longitudinal strain in diagnosing <scp>AL</scp> amyloid cardiomyopathy. Echocardiography, 2018, 35, 1764-1771.	0.3	3
203	Normative reference ranges for echocardiographic chamber dimensions in a healthy Central European population: results from the Czech post-MONICA survey. Cardiovascular Ultrasound, 2019, 17, 22.	0.5	3
204	Systematic COronary Risk Evaluation (SCORE) and 20-year risk of cardiovascular mortality and cancer. European Journal of Internal Medicine, 2020, 79, 63-69.	1.0	3
205	Prospective follow-up in various subtypes of cardiomyopathies: insights from the ESC EORP Cardiomyopathy Registry. European Heart Journal Quality of Care & Clinical Outcomes, 2021, 7, 134-142.	1.8	3
206	Prevalence of Fabry disease in men with tinnitus and sensorineural hearing loss. Journal of Applied Biomedicine, 2021, 19, 57-61.	0.6	3
207	Usefulness of Alcohol Septal Ablation in the Left Ventricular Outflow Tract Obstruction in Fabry Disease Cardiomyopathy. American Journal of Cardiology, 2021, 150, 110-113.	0.7	3
208	Detailed Phenotype of GLA Variants Identified by the Nationwide Neurological Screening of Stroke Patients in the Czech Republic. Journal of Clinical Medicine, 2021, 10, 3543.	1.0	3
209	Non-invasive endothelial function assessment using digital reactive hyperaemia correlates with three-dimensional intravascular ultrasound and virtual histology-derived plaque volume and plaque phenotype. Kardiologia Polska, 2016, 74, 1485-1491.	0.3	3
210	Absence of Borrelia burgdorferi in the myocardium of subjects with normal left ventricular systolic function: a study using PCR and electron microscopy. Biomedical Papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia, 2016, 160, 136-139.	0.2	3
211	Left atrial flow propagation velocity: a new approach for assessment of left atrial reservoir function. International Journal of Cardiovascular Imaging, 2011, 27, 75-82.	0.7	2
212	Functional variants of <i>eNOS</i> and <i>iNOS</i> genes have no relationship to the portal hypertension in patients with liver cirrhosis. Scandinavian Journal of Gastroenterology, 2013, 48, 592-601.	0.6	2
213	A rare case of regressively changed lipomatous hypertrophy of the interatrial septum presenting with anemia and recurrent fever. Cardiovascular Pathology, 2016, 25, 161-164.	0.7	2
214	Summary of 2015 ESC Guidelines for the diagnosis and management of pericardial diseases. Prepared by the Czech Society of Cardiology. Cor Et Vasa, 2016, 58, e81-e106.	0.1	2
215	Pathologic Intimal Thickening Plaque Phenotype: Not as Innocent as Previously Thought. A Serial 3D Intravascular Ultrasound Virtual Histology Study. Revista Espanola De Cardiologia (English Ed), 2017, 70, 25-33.	0.4	2
216	3D electroanatomical mapping is less sensitive to atrial remodeling in estimation of true left atrial volume than echocardiography. BMC Medical Imaging, 2018, 18, 32.	1.4	2

ALES LINHART

#	Article	IF	CITATIONS
217	Refractory Ventricle Arrhythmias Alternating with Pulseless Electrical Activity in a Young Woman Rescued by Extracorporeal Cardiopulmonary Resuscitation. Case Reports in Medicine, 2018, 2018, 1-4.	0.3	2
218	Conundrum of implantable electric devices in Anderson-Fabry cardiomyopathy. Heart, 2019, 105, 1775-1776.	1.2	2
219	Giant cell myocarditis in an older patient – reassessing the threshold for endomyocardial biopsy. ESC Heart Failure, 2020, 7, 3165-3168.	1.4	2
220	Heart rate as an independent predictor of long term mortality of acute heart failure patients in sinus rhythm according to their ejection fraction: data from the AHEAD registry. European Journal of Internal Medicine, 2020, 78, 88-94.	1.0	2
221	Successfully Resuscitated Sudden Cardiac Death in a Young Homosexual Male with HIV Myocarditis. Current HIV Research, 2009, 7, 434-436.	0.2	2
222	Carotid intima-media thickness in young survivors of acute myocardial infarction. Experimental and Clinical Cardiology, 2012, 17, 215-20.	1.3	2
223	Association between tyrosine hydroxylase polymorphisms and left ventricular structure in young normotensive men. British Journal of Biomedical Science, 2002, 59, 90-4.	1.2	2
224	Anderson-Fabry disease: No histological signs of pathological accumulation in arterial and venous endothelium during pegunigalsidase alfa therapy. Kardiologia Polska, 2021, 79, 1385-1386.	0.3	2
225	Pulmonary arterial hypertension – the challenge in diagnosis and treatment. Current Medical Research and Opinion, 2007, 23, S3-S9.	0.9	1
226	Reduced Thrombin Generation and Soluble P-selectin After Intravenous Enoxaparin During PCI. Cardiovascular Drugs and Therapy, 2011, 25, 243-250.	1.3	1
227	A high frequency of viral agents yet absence of Borrelia burgdorferi is seen within the myocardium of subjects with normal left ventricular systolic function: an electron microscopy study. Folia Microbiologica, 2016, 61, 129-135.	1.1	1
228	Prompt agalsidase alfa therapy initiation after symptom onset is associated with improved renal and cardiovascular outcomes in the Fabry Outcome Survey. Molecular Genetics and Metabolism, 2017, 120, S85.	0.5	1
229	Population pharmacokinetics of riociguat and its metabolite in patients with chronic thromboembolic pulmonary hypertension from routine clinical practice. Pulmonary Circulation, 2020, 10, 1-11.	0.8	1
230	Comparison of early diastolic mitral annular velocity and flow propagation velocity in detection of mild to moderate left ventricular diastolic dysfunction. , 0, .		1
231	The Heart in Fabry Disease – from Pathogenesis to Enzyme Replacement Therapy. , 2010, , 189-210.		1
232	Metabolic Cardiomyopathy. , 2020, , 151-166.		1
233	Expert consensus on the practical aspects of the cooperation of cardiologist and diabetologist in the management of the patients with chronic heart failure and reduced ejection fraction. Vnitrni Lekarstvi, 2021, 67, 404-410.	0.1	1

#	Article	IF	CITATIONS
235	Pulmonary artery pulsatility indexes in differentiating chronic pulmonary thromboembolism from pulmonary arterial hypertension. Current Medical Research and Opinion, 2007, 23, S35-S41.	0.9	0
236	TCT-161 Long term effect of transcatheter intra-arterial administration of bone marrow mononuclear cells in patients with critical limb ischemia. Journal of the American College of Cardiology, 2012, 60, B46-B47.	1.2	0
237	Hybrid myocardial revascularization - the cardiologist's view. Cor Et Vasa, 2012, 54, e188-e201.	0.1	0
238	Prediction of coronary vessel involvement on the basis of atherosclerosis risk factor analysis. Bratislava Medical Journal, 2013, 114, 413-417.	0.4	0
239	TCT-353 Pathologic Intimal Thickening Plaque Phenotype - Not As Innocent As We Though. Study With 3D Intravascular Ultrasound And Virtual Histology. Journal of the American College of Cardiology, 2014, 64, B103.	1.2	0
240	TCT-96 Progression of coronary atherosclerosis despite lipid-lowering therapy in diabetic patients compared to non-dibetic ones. Study with 3D intravascular ultrasound and virtual histology. Journal of the American College of Cardiology, 2016, 68, B39.	1.2	0
241	A complicated diagnosis of constrictive pericarditis in a patient with atrial fibrillation - The importance of temporary pacing inducing regular heart rhythm during invasive hemodynamic study. Cor Et Vasa, 2017, 59, e460-e464.	0.1	0
242	Validation of new marker of fluid responsiveness based on Doppler assessment of blood flow velocity in superior vena cava in mechanically ventilated pigs. Intensive Care Medicine Experimental, 2018, 6, 36.	0.9	0
243	Importance of endomyocardial biopsy in distinguishing between cardiac sarcoidosis and giant cell myocarditis. Wiener Klinische Wochenschrift, 2019, 131, 186-187.	1.0	0
244	Current cardiovascular research at the Charles University: the â€~PRAGUE' trials and beyond. European Heart Journal Supplements, 2020, 22, F6-F13.	0.0	0
245	Intracoronary delivery of stem cells in patients with acute myocardial infarction. The clinical experience obtained to date and prospects. Cor Et Vasa, 2009, 51, 513-519.	0.1	0
246	Echocardiographic assessment of left ventricular diastolic function: what we able to do in 2009. Cor Et Vasa, 2009, 51, 789-804.	0.1	0
247	Tako-tsubo cardiomyopathy with both ventricles involvement. Cor Et Vasa, 2011, 53, 555-558.	0.1	0
248	Fabry disease. Interni Medicina Pro Praxi, 2018, 20, 10-13.	0.0	0
249	Reply. Journal of Hypertension, 2020, 38, 1860-1861.	0.3	0
250	(Statistically speaking, sports is healthy for your heart, but statistics can be tricky). Cor Et Vasa, 2020, 62, 351-352.	0.1	0
251	(Expert consensus on the practical aspects of collaboration between cardiologists and) Tj ETQq1 1 0.784314 rgBT	/Overlock 0.1	x 10 Tf 50 0

#	Article	IF	CITATIONS
253	Title is missing!. , 2020, 15, e0232845.		0
254	Title is missing!. , 2020, 15, e0232845.		0